Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
13.58
-0.01 (-0.07%)
At close: Aug 1, 2025, 4:00 PM
13.60
+0.02 (0.15%)
After-hours: Aug 1, 2025, 6:04 PM EDT

Company Description

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions.

The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.

Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Oruka Therapeutics, Inc.
Oruka Therapeutics logo
CountryUnited States
Founded2004
IndustryBiotechnology
SectorHealthcare
Employees28
CEOLawrence Klein

Contact Details

Address:
855 Oak Grove Avenue, Suite 100
Menlo Park, California 94025
United States
Phone(650) 606-7910
Websiteorukatx.com

Stock Details

Ticker SymbolORKA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000907654
CUSIP Number687604108
ISIN NumberUS6876041087
Employer ID36-3855489
SIC Code2834

Key Executives

NamePosition
Dr. Lawrence Otto Klein Ph.D.President, Chief Executive Officer and Director
Paul T. QuinlanGeneral Counsel and Secretary
Dr. Joana Goncalves M.D.Chief Medical Officer
Arjun Agarwal CPASenior Vice President of Finance and Treasurer
Laura SandlerChief Operating Officer
Alan LadaVice President of Investor Relations
Christopher FinchVice President of Corporate Development and Strategy
Dr. Rajiv PanwarVice President and Head of Chemistry, Manufacturing and Controls
Dr. Joe Senn Ph.D.Senior Vice President of Nonclinical Research and Development

Latest SEC Filings

DateTypeTitle
Jul 17, 2025SCHEDULE 13GFiling
Jul 1, 20258-KCurrent Report
Jun 3, 20258-KCurrent Report
May 15, 2025SCHEDULE 13GFiling
May 14, 2025424B3Prospectus
May 14, 202510-QQuarterly Report
May 13, 2025SCHEDULE 13GFiling
Apr 18, 2025ARSFiling
Apr 18, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 18, 2025DEF 14AOther definitive proxy statements